Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis

Yohei Hisada; Nigel Mackman

doi:10.1055/s-0039-1687894

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2019; 45(04): 385-395
DOI: 10.1055/s-0039-1687894

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis

Authors

Yohei Hisada

¹Division of Hematology and Oncology, Department of Medicine, Thrombosis and Hemostasis Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Nigel Mackman

¹Division of Hematology and Oncology, Department of Medicine, Thrombosis and Hemostasis Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Abstract

There is a strong relationship between tissue factor (TF) and cancer. Many cancer cells express high levels of both full-length TF and alternatively spliced (as) TF. TF expression in cancer is associated with poor prognosis. In this review, the authors summarize the regulation of TF expression in cancer cells and the roles of TF and asTF in tumor growth and metastasis. A variety of different signaling pathways, transcription factors and micro ribonucleic acids regulate TF gene expression in cancer cells. The TF/factor VIIa complex enhances tumor growth by activating protease-activated receptor 2 signaling and by increasing the expression of angiogenic factors, such as vascular endothelial growth factor. AsTF increases tumor growth by enhancing integrin β1 signaling. TF and asTF also contribute to metastasis via multiple thrombin-dependent and independent mechanisms that include protecting tumor cells from natural killer cells. Finally, a novel anticancer therapy is using tumor TF as a target to deliver cytotoxic drugs to the tumor. TF may be useful in diagnosis, prognosis, and treatment of cancer.

Keywords

cancer - metastasis - thrombosis - tissue factor - tumor

Full Text

References

References
1 Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol 2018; 38 (04) 709-725
2 Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9 (04) 458-462
3 Censarek P, Bobbe A, Grandoch M, Schrör K, Weber AA. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb Haemost 2007; 97 (01) 11-14
4 Bogdanov VY, Versteeg HH. “Soluble Tissue Factor” in the 21st century: definitions, biochemistry, and pathophysiological role in thrombus formation. Semin Thromb Hemost 2015; 41 (07) 700-707
5 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134 (05) 1087-1097
6 Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013; 122 (11) 1873-1880
7 Nitori N, Ino Y, Nakanishi Y. , et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005; 11 (07) 2531-2539
8 Kaido T, Oe H, Yoshikawa A, Mori A, Arii S, Imamura M. Tissue factor is a useful prognostic factor of recurrence in hepatocellular carcinoma in 5-year survivors. Hepatogastroenterology 2005; 52 (65) 1383-1387
9 Seto S, Onodera H, Kaido T. , et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000; 88 (02) 295-301
10 Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83 (02) 164-170
11 Akashi T, Furuya Y, Ohta S, Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003; 62 (06) 1078-1082
12 Patry G, Hovington H, Larue H, Harel F, Fradet Y, Lacombe L. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. Int J Cancer 2008; 122 (07) 1592-1597
13 Yamashita H, Kitayama J, Ishikawa M, Nagawa H. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol 2007; 95 (04) 324-331
14 Chen L, Luo G, Tan Y. , et al. Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient. Acta Histochem 2010; 112 (03) 233-239
15 Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003; 9 (14) 5339-5345
16 Zelaya H, Rothmeier AS, Ruf W. Tissue factor at the crossroad of coagulation and cell signaling. J Thromb Haemost 2018; 16 (10) 1941-1952
17 Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005; 25 (08) 1545-1550
18 Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med 2015; 5 (04) pii:a006098
19 Rak J, Mitsuhashi Y, Bayko L. , et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55 (20) 4575-4580
20 Rak J, Mitsuhashi Y, Sheehan C. , et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000; 60 (02) 490-498
21 Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65 (04) 1406-1413
22 Provençal M, Labbé D, Veitch R. , et al. c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. Carcinogenesis 2009; 30 (07) 1089-1096
23 Rong Y, Belozerov VE, Tucker-Burden C. , et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009; 69 (06) 2540-2549
24 Unruh D, Schwarze SR, Khoury L. , et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol 2016; 132 (06) 917-930
25 D'Asti E, Huang A, Kool M. , et al. Tissue factor regulation by miR-520g in primitive neuronal brain tumor cells: a possible link between Oncomirs and the vascular tumor microenvironment. Am J Pathol 2016; 186 (02) 446-459
26 Zhou JN, Ljungdahl S, Shoshan MC, Swedenborg J, Linder S. Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway. Mol Carcinog 1998; 21 (04) 234-243
27 Yu JL, Xing R, Milsom C, Rak J. Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1. Thromb Res 2010; 126 (01) e6-e10
28 Sun L, Liu Y, Lin S. , et al. Early growth response gene-1 and hypoxia-inducible factor-1α affect tumor metastasis via regulation of tissue factor. Acta Oncol 2013; 52 (04) 842-851
29 Bourcy M, Suarez-Carmona M, Lambert J. , et al. Tissue factor induced by epithelial-mesenchymal transition triggers a procoagulant state that drives metastasis of circulating tumor cells. Cancer Res 2016; 76 (14) 4270-4282
30 Zhang X, Yu H, Lou JR. , et al. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem 2011; 286 (02) 1429-1435
31 Teruel R, Pérez-Sánchez C, Corral J. , et al. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost 2011; 9 (10) 1985-1992
32 Yu JL, May L, Lhotak V. , et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105 (04) 1734-1741
33 Rao B, Gao Y, Huang J. , et al. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. Int J Colorectal Dis 2011; 26 (05) 593-601
34 Yu G, Li H, Wang X. , et al. MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. Mol Cell Biochem 2013; 380 (1-2): 239-247
35 Lewis CS, Elnakat Thomas H, Orr-Asman MA. , et al. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors. J Thromb Haemost 2019; 17 (01) 169-182
36 Milsom CC, Yu JL, Mackman N. , et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res 2008; 68 (24) 10068-10076
37 Kato S, Pinto M, Carvajal A. , et al. Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. Thromb Haemost 2005; 94 (02) 444-453
38 Regina S, Rollin J, Bléchet C, Iochmann S, Reverdiau P, Gruel Y. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol 2008; 3 (07) 689-697
39 Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. EMT and MET: necessary or permissive for metastasis?. Mol Oncol 2017; 11 (07) 755-769
40 Garnier D, Magnus N, Lee TH. , et al. Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem 2012; 287 (52) 43565-43572
41 Dang L, White DW, Gross S. , et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462 (7274): 739-744
42 Turcan S, Rohle D, Goenka A. , et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483 (7390): 479-483
43 Chuang TD, Luo X, Panda H, Chegini N. miR-93/106b and their host gene, MCM7, are differentially expressed in leiomyomas and functionally target F3 and IL-8. Mol Endocrinol 2012; 26 (06) 1028-1042
44 D'Asti E, Anderson GM, Rak J. Inhibition of tissue factor signaling in breast tumour xenografts induces widespread changes in the microRNA expression profile. Biochem Biophys Res Commun 2017; 494 (3-4): 700-705
45 Magnus N, Gerges N, Jabado N, Rak J. Coagulation-related gene expression profile in glioblastoma is defined by molecular disease subtype. J Thromb Haemost 2013; 11 (06) 1197-1200
46 Tawil N, Chennakrishnaiah S, Bassawon R, Johnson R, D'Asti E, Rak J. Single cell coagulomes as constituents of the oncogene-driven coagulant phenotype in brain tumours. Thromb Res 2018; 164 (Suppl. 01) S136-S142
47 Magnus N, Garnier D, Meehan B. , et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A 2014; 111 (09) 3544-3549
48 Hisada Y, Mackman N. Mouse models of cancer-associated thrombosis. Thromb Res 2018; 164 (Suppl. 01) S48-S53
49 McEachron T, Mackman N. Tumors, ticks and tissue factor. J Thromb Haemost 2009; 7 (11) 1852-1854
50 Wang JG, Geddings JE, Aleman MM. , et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012; 119 (23) 5543-5552
51 Geddings JE, Hisada Y, Boulaftali Y. , et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost 2016; 14 (01) 153-166
52 Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 2004; 29 (03) 193-203
53 DeRose YS, Wang G, Lin YC. , et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011; 17 (11) 1514-1520
54 Zhao X, Liu Z, Yu L. , et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro-oncol 2012; 14 (05) 574-583
55 McEvoy J, Ulyanov A, Brennan R. , et al. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS One 2012; 7 (08) e42739
56 Ruf W. Tissue factor and cancer. Thromb Res 2012; 130 (Suppl. 01) S84-S87
57 Zhang Y, Deng Y, Luther T. , et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94 (03) 1320-1327
58 Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RC. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg 1999; 86 (07) 890-894
59 Koizume S, Jin MS, Miyagi E. , et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006; 66 (19) 9453-9460
60 Hembrough TA, Swartz GM, Papathanassiu A. , et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003; 63 (11) 2997-3000
61 Zhao J, Aguilar G, Palencia S, Newton E, Abo A. rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res 2009; 15 (01) 208-216
62 Versteeg HH, Schaffner F, Kerver M. , et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111 (01) 190-199
63 Palumbo JS, Talmage KE, Massari JV. , et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007; 110 (01) 133-141
64 Hjortoe GM, Petersen LC, Albrektsen T. , et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004; 103 (08) 3029-3037
65 Versteeg HH, Schaffner F, Kerver M. , et al. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res 2008; 68 (17) 7219-7227
66 Schaffner F, Versteeg HH, Schillert A. , et al. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood 2010; 116 (26) 6106-6113
67 Rydén L, Grabau D, Schaffner F, Jönsson PE, Ruf W, Belting M. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer 2010; 126 (10) 2330-2340
68 Rothmeier AS, Liu E, Chakrabarty S. , et al. Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling. Blood 2018; 131 (06) 674-685
69 Yu J, May L, Milsom C. , et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 2008; 28 (11) 1975-1981
70 Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003; 162 (05) 1503-1513
71 Keshava S, Sahoo S, Tucker TA, Idell S, Rao LV, Pendurthi UR. Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor. Cancer Res 2013; 73 (13) 3963-3973
72 Tekin C, Shi K, Daalhuisen JB, Ten Brink MS, Bijlsma MF, Spek CA. PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. Oncotarget 2018; 9 (62) 32010-32023
73 Queiroz KC, Shi K, Duitman J. , et al. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Int J Cancer 2014; 135 (10) 2294-2304
74 Adams GN, Sharma BK, Rosenfeldt L. , et al. Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice. J Thromb Haemost 2018; 16 (11) 2258-2269
75 Hobbs JE, Zakarija A, Cundiff DL. , et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007; 120 (Suppl. 02) S13-S21
76 Kocatürk B, Van den Berg YW, Tieken C. , et al. Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci U S A 2013; 110 (28) 11517-11522
77 Kocatürk B, Tieken C, Vreeken D. , et al. Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression. J Thromb Haemost 2015; 13 (09) 1683-1693
78 Unruh D, Ünlü B, Lewis CS. , et al. Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma. Oncotarget 2016; 7 (18) 25264-25275
79 Unruh D, Turner K, Srinivasan R. , et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer 2014; 134 (01) 9-20
80 Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog 2013; 18 (1-2): 43-73
81 Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2 (08) 563-572
82 Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80 (06) 894-898
83 Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A 1992; 89 (24) 11832-11836
84 Gil-Bernabé AM, Ferjancic S, Tlalka M. , et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012; 119 (13) 3164-3175
85 Amirkhosravi A, Meyer T, Chang JY. , et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002; 87 (06) 930-936
86 Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A 1995; 92 (18) 8205-8209
87 Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998; 101 (07) 1372-1378
88 Yokota N, Zarpellon A, Chakrabarty S. , et al. Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. J Thromb Haemost 2014; 12 (01) 71-81
89 Palumbo JS, Kombrinck KW, Drew AF. , et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96 (10) 3302-3309
90 Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62 (23) 6966-6972
91 Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104 (02) 397-401
92 Palumbo JS, Talmage KE, Massari JV. , et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105 (01) 178-185
93 Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004; 2 (07) 395-402
94 Villares GJ, Zigler M, Dobroff AS. , et al. Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proc Natl Acad Sci U S A 2011; 108 (02) 626-631
95 Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275 (5299): 547-550
96 Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58 (20) 4646-4653
97 Liu C, Huang H, Doñate F. , et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 2002; 62 (19) 5470-5475
98 El-Sheikh A, Borgstrom P, Bhattacharjee G, Belting M, Edgington TS. A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment. Cancer Res 2005; 65 (23) 11109-11117
99 Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A 1999; 96 (14) 8161-8166
100 Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci U S A 2000; 97 (16) 9221-9225
101 Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci U S A 2001; 98 (21) 12180-12185
102 Yamamoto Y, Hyodo I, Koga Y. , et al. Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models. Cancer Sci 2015; 106 (05) 627-634
103 Sugaya A, Hyodo I, Koga Y. , et al. Utility of epirubicin-incorporating micelles tagged with anti-tissue factor antibody clone with no anticoagulant effect. Cancer Sci 2016; 107 (03) 335-340
104 Breij EC, de Goeij BE, Verploegen S. , et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014; 74 (04) 1214-1226
105 Koga Y, Manabe S, Aihara Y. , et al. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Int J Cancer 2015; 137 (06) 1457-1466
106 Zhang X, Li Q, Zhao H. , et al. Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma. Oncotarget 2017; 8 (35) 59086-59102
107 Francisco JA, Cerveny CG, Meyer DL. , et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102 (04) 1458-1465
108 Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. J Control Release 2018; 284: 49-56